Up to €37.5m investment from the EIB, consisting of €10m upfront with optionality to further increase by an additional €27.5m…
Read More
Xeltis
De Lismortel 31
5612 AR Eindhoven
The Netherlands
info@xeltis.com
+31 40 751 7614
The Journal of Vascular Access. aXess FIH 12m follow-up & clinical histopathology Abstract Background: Xeltis’ aXess hemodialysis (HD) conduit is…
Read More
Complete EU pivotal trial data highlights transformative potential of aXess in hemodialysis treatment Primary endpoint met with standout sustained patency…
Read More
Computers in Biology and Medicine. ETR computational modeling validated with Xeltis sheep data
Read More
Preliminary clinical data from Xabg, Xeltis’ coronary artery bypass conduit (CABG), demonstrating positive safety and patency In an earlier, separate…
Read More
Xeltis is one of only seven companies to successfully pass evaluation phase of EIC Strategic Technologies for Europe Platform (STEP)…
Read More
Leading nephrologists Dr. An De Vriese and Dr. Monnie Wasse join as Company continues clinical advancement EINDHOVEN, The Netherlands, 11…
Read More
Histological assessment of a novel restorative coronary artery bypass graft in a chronic ovine model
Frontiers in Bioengineering and Biotechnology. XABG 12 months sheep histology
Read More
Interdisciplinary CardioVascular and Thoracic Surgery. XABG Clinical Case report 1 year patency
Read More
Enrolment completed - 120 patients with end-stage renal disease in 22 centers in Europe Primary endpoint readouts anticipated in Q2…
Read More